IAG is Presenting at Society of Neuro-Oncology Meeting
IAG team and Julia O’Lynn, IAG’s Director of Bio Innovation and Strategic Partnerships, will be attending the Society of Neuro-Oncology (SNO 2022) 27th Annual Meeting and Educational Day in Tampa, Florida, on November 16 – 20, 2022.
IAG’s team will be meeting with biotech companies and addressing their challenges including trial design, dealing with pseudo-progression, finding optimal endpoints to demonstrate novel therapeutics’ efficacy. We will speak about our platform DYNAMIKA and use of Artificial Intelligence in neuro-oncology trials and explore how IAG’s novel strategies, including advanced imaging biomarkers and AI can support precision medicine and drug development.
Together with our biotech partner CNS Pharmaceuticals Inc., we will be presenting the preliminary results from a randomized, controlled trial of Berubicin.
Currently, 31 patients are enrolled with 21 in the Berubicin arm and 10 in the Lomustine arm. Trial design: https://clinicaltrials.gov/ct2/show/NCT04762069 The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. This study will evaluate the efficacy of this novel drug and potentially provide therapeutic options for patients after first-line therapy. An updated profile of the patient population, safety, and initial efficacy will be presented.
A randomized, controlled trial of Berubicin, a topoisomerase II poison that crosses the blood-brain barrier (BBB), after first-line therapy for glioblastoma multiforme (GBM): Preliminary Results, Authors: S. Silberman, J. O’Lynn, O. Kubassova
If you are not attending and would like to request a poster or to schedule a call: email@example.com
About IAG, Image Analysis Group
IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.
IAG takes a holistic approach to biotech’s clinical development and brings together:
- An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
- Patented methodologies for quantitative assessment of treatment efficacy and safety
- Expertise in detecting treatment effects including pseudo-progression and pseudo-response
- Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
- Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.
About SNO, the Society for Neuro-Oncology
The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. click here.